Literature DB >> 25173609

miR-125b inhibits hepatitis B virus expression in vitro through targeting of the SCNN1A gene.

Zhenzhen Zhang1, Juan Chen, Yin He, Xue Zhan, Ruiqiu Zhao, Yanfeng Huang, Hongmei Xu, Zhaomin Zhu, Quanbo Liu.   

Abstract

microRNAs (miRNAs) are small noncoding RNAs that modulate gene expression at the posttranscriptional level, playing an important role in many diseases. However, reports concerning the role of miRNA in hepatitis B virus (HBV) infection are limited. miRNA chips were used to investigate miRNA changes during HBV infection in vitro. Bioinformatics analysis was used to explore possible miRNA and target genes during HBV infection. The expression of miR-125b and its potential target gene, sodium channel, non-voltage-gated 1 alpha (SCNN1A), was further analyzed. A total of 136 miRNAs were analyzed in an HBV transient transfection model (HepG2-HBV1.3), and 78 miRNAs were differentially expressed in HepG2.2.15 cells compared with HepG2 cells. miR-125b expression was decreased in both HepG2-HBV1.3 and HepG2.2.15 cells, and ectopic expression of miR-125b inhibited HBV DNA intermediates and secretion of HBsAg and HBeAg. miR-125b also inhibited the mRNA and protein levels of SCNN1A. Using a dual luciferase reporter system, we found that SCNN1A was one of the targets of miR-125b. In this study, we found that miR-125b inhibits HBV expression in vitro by regulating SCNN1A expression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25173609     DOI: 10.1007/s00705-014-2208-y

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  15 in total

Review 1.  Bioelectrical controls of morphogenesis: from ancient mechanisms of cell coordination to biomedical opportunities.

Authors:  Jessica L Whited; Michael Levin
Journal:  Curr Opin Genet Dev       Date:  2019-08-20       Impact factor: 5.578

Review 2.  Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential.

Authors:  Yuchen Xia; Haitao Guo
Journal:  Antiviral Res       Date:  2020-05-22       Impact factor: 5.970

Review 3.  Hepatitis B virus and microRNAs: Complex interactions affecting hepatitis B virus replication and hepatitis B virus-associated diseases.

Authors:  Jason Lamontagne; Laura F Steel; Michael J Bouchard
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

Review 4.  Host cellular microRNA involvement in the control of hepatitis B virus gene expression and replication.

Authors:  Yoshiaki Mizuguchi; Toshihiro Takizawa; Eiji Uchida
Journal:  World J Hepatol       Date:  2015-04-08

Review 5.  MicroRNAs as Important Players in Host-hepatitis B Virus Interactions.

Authors:  Bouchra Kitab; Hanane Salih Alj; Sayeh Ezzikouri; Soumaya Benjelloun
Journal:  J Clin Transl Hepatol       Date:  2015-06-15

6.  Expression Profiling of Cellular MicroRNA in Asymptomatic HBsAg Carriers and Chronic Hepatitis B Patients.

Authors:  Xianliang Hou; Yan Liang; Jianing Chen; Yingfeng Wei; Ping Zeng; Lin Wang; Chong Lu; Hongyan Diao
Journal:  Biomed Res Int       Date:  2017-08-23       Impact factor: 3.411

7.  Serum microRNA signatures as "liquid biopsies" for interrogating hepatotoxic mechanisms and liver pathogenesis in human.

Authors:  Julian Krauskopf; Theo M de Kok; Shelli J Schomaker; Mark Gosink; Deborah A Burt; Patricia Chandler; Roscoe L Warner; Kent J Johnson; Florian Caiment; Jos C Kleinjans; Jiri Aubrecht
Journal:  PLoS One       Date:  2017-05-17       Impact factor: 3.240

Review 8.  Hepatitis B Virus Infection, MicroRNAs and Liver Disease.

Authors:  Neelakshi Sarkar; Runu Chakravarty
Journal:  Int J Mol Sci       Date:  2015-08-03       Impact factor: 5.923

9.  Alteration of microRNA profiles by a novel inhibitor of human La protein in HBV-transformed human hepatoma cells.

Authors:  Jiaqian Pan; Shuangmei Tong; Jing Tang
Journal:  J Med Virol       Date:  2017-09-22       Impact factor: 2.327

Review 10.  Membrane Transporters and Channels in Melanoma.

Authors:  Ines Böhme; Roland Schönherr; Jürgen Eberle; Anja Katrin Bosserhoff
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.